U
CPRX

UBS’s Catalyst Pharmaceutical CPRX Stock Holding History

UBS’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$1K Sell
300
-1,800
-86% -$4.7K ﹤0.01% 10137
2014
Q2 		$5K Buy
2,100
+900
+75% +$1.92K ﹤0.01% 9490
2014
Q1 		$3K Buy
1,200
+200
+20% +$418 ﹤0.01% 9824
2013
Q4 		$2K Buy
+1,000
New +$2.02K ﹤0.01% 10013

Other funds holding CPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS's CPRX Position: Q2 2014 in Review

UBS sold out of Catalyst Pharmaceutical (CPRX) in Q2 2014, closing a stake of 32,551 shares — an estimated $69.5K sold.

UBS first reported a position in CPRX in Q2 2013 and held it in 2 quarters. The position peaked at $74K in Q1 2014. 47 funds tracked by Wall St. Rank hold CPRX as of Q2 2014.

  • UBS reported no remaining Catalyst Pharmaceutical position as of Q2 2014 after selling out during the quarter.
  • UBS sold 32,551 Catalyst Pharmaceutical shares in Q2 2014, an estimated $69.5K.
  • UBS first reported a position in Catalyst Pharmaceutical in Q2 2013 and held it in 2 quarters.
  • UBS's Catalyst Pharmaceutical position peaked at $74K in Q1 2014.
  • 47 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2014.

Based on UBS's 13F filing for Q2 2014, filed 14 Aug 2014.